Inspire Medical Systems, Inc. (NYSE:INSP) Stock Has Average Target Price of $68.82

Inspire Medical Systems, Inc. (NYSE:INSP) has been assigned an average rating of “Hold” from the twenty brokerages that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $68.82.

A number of equities analysts recently issued reports on INSP shares. Royal Bank Of Canada increased their target price on shares of Inspire Medical Systems from $60.00 to $75.00 and gave the company a “sector perform” rating in a research report on Thursday, October 1st. Truist Financial boosted their target price on Inspire Medical Systems from $62.00 to $78.00 and gave the stock a “hold” rating in a research report on Wednesday, October 14th. UBS Group assumed coverage on Inspire Medical Systems in a report on Tuesday, July 28th. They set a “sell” rating and a $39.00 price objective on the stock. Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target for the company in a research report on Tuesday, August 4th. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $71.15 on Monday. The firm has a fifty day moving average of $68.26 and a 200-day moving average of $59.23. The company has a market cap of $2.06 billion, a price-to-earnings ratio of 15.40, a price-to-earnings-growth ratio of 5.38 and a beta of 0.73. Inspire Medical Systems has a 1 year low of $38.91 and a 1 year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Analysts predict that Inspire Medical Systems will post 1.24 EPS for the current year.

Insider Activity at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Inspire Medical Systems

Institutional investors and hedge funds have recently bought and sold shares of the business. WINTON GROUP Ltd increased its stake in shares of Inspire Medical Systems by 790.8% during the 2nd quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock worth $1,669,000 after purchasing an additional 33,212 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Inspire Medical Systems in the 2nd quarter valued at $2,732,000. Alberta Investment Management Corp acquired a new stake in shares of Inspire Medical Systems in the 2nd quarter valued at $5,483,000. Empowered Funds LLC bought a new stake in Inspire Medical Systems in the second quarter worth $2,260,000. Finally, GSA Capital Partners LLP bought a new stake in Inspire Medical Systems in the second quarter worth $820,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.